Partnership set to make therapies ‘reach patients sooner’ 

A new partnership could accelerate clinical trials and bring therapies to patients sooner. 

Clinical research organisation ICON has partnered with Advarra to introduce a new ‘research-ready’ site network model for clinical trials, set to address major bottlenecks. 

The partnership will integrate ICON’s global clinical trial solutions and services with Advarra’s site CTMSs, eISF, and eSource systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.  

The approach leverages Advarra’s Study Collaboration as the connector to ICON’s proprietary technology to create a shared operating environment for ICON studies that reduces administrative friction, accelerates study startup, and increases clinical trial participation. 

Advarra will also provide ICON with deep operational intelligence through Braid, the company’s data and AI platform drawing on operational insights from its IRB and clinical trial systems. The intelligence could help ICON further optimise protocol design, improve forecasting and study planning, and strengthen research site identification and feasibility decisions.  

“Research sites should not have to adapt their operations for every new study or sponsor, and ICON and Advarra are focused on meeting sites where they are, prioritising their needs and removing that burden through this partnership,” said Barry Balfe, CEO of ICON.  

“By aligning ICON’s workflows with the systems sites already use every day, we’re advancing a more practical and scalable way to run trials that reduces administrative burden on sites.” 

“Sites do their best work when they can stay focused on patients and study delivery, not on managing fragmented processes,” said Gadi Saarony, CEO of Advarra.  

“By integrating ICON’s technology with the Advarra systems sites already use, this partnership allows sites to work in their native systems, reducing rework, improving consistency, and streamlining workflows.  

“For sponsors, it means trials can move forward with greater speed and confidence, helping promising therapies move through development more efficiently and reach patients sooner.” 

The post Partnership set to make therapies ‘reach patients sooner’  appeared first on Drug Discovery World (DDW).